Kuehn Law, PLLC has launched an investigation into the company following allegations that insiders touted the Zio AT as an innovative growth product while omitting critical details regarding its specific market application. Investors who purchased iRhythm common stock prior to November 5, 2021, are being urged to review their legal standing.

Shareholders who believe they were affected by these disclosures are encouraged to contact Sophia Anne Silayan at (833) 672-0814 or via email. The firm handles such litigation on a contingency basis, covering all case costs for clients. Given the time-sensitive nature of these enforcement actions, legal representatives advise interested parties to reach out immediately to discuss potential participation in the derivative litigation.